The management of irritable bowel syndrome: A European, primary and secondary care collaboration

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 8, 2001, Pages 933-939

  Grant Thompson, W ^a   Hungin, Amritpal P S ^b   Neri, Matteo ^c   Holtmann, Gerald ^d   Sofos, Sotirios ^e   Delvaux, Michel ^f   Caballero Plasencia, Antonio ^g  

^a UNIVERSITY OF OTTAWA   (Canada)

^b DURHAM UNIVERSITY   (United Kingdom)

^c d Annunzio University   (Italy)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e Health Centre of Motril Este   (Spain)

^f Universitie de Toulouse   (France)

^g UNIVERSITY OF GRANADA   (Spain)

Author keywords

Europe; General practitioner; Irritable bowel syndrome; Management

Indexed keywords

ALOSETRON; AMITRIPTYLINE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CIMETROPIUM; DESIPRAMINE; DIPHENOXYLATE; HERBACEOUS AGENT; ISPAGULA; KAPPA OPIATE RECEPTOR AGONIST; LAXATIVE; LOPERAMIDE; MEBEVERINE; OPIATE; OTILONIUM BROMIDE; PINAVERIUM BROMIDE; PROBIOTIC AGENT; SENNA EXTRACT; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE;

ARTICLE; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DIET THERAPY; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; GENERAL PRACTICE; HUMAN; HYPERICUM PERFORATUM; HYPNOSIS; IRRITABLE COLON; LACTOBACILLUS PLANTARUM; LIFESTYLE; MEDICAL SPECIALIST; META ANALYSIS; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE;

COLONIC DISEASES, FUNCTIONAL; EUROPE; FAMILY PRACTICE; GASTROENTEROLOGY; HUMANS; PATIENT EDUCATION;

EID: 0034879462     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200108000-00010     Document Type: Article

References (48)

1. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980; 79: 283-288.
2. Drossman DA, Sandler RS, McKee DC, Lovitz AJ. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982; 83: 529-534.
3. Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees: prevalence, demographics and clinical correlates. Dig Dis Sci 1993; 38: 1581-1589.
4. Bommelaer G, Rouch M, Dapoigny M, Pais D, Loisy P, Gualino M. et al. Epidemiology of functional bowel disorders in apparently healthy people. Gastroenterol Clin Biol 1986; 10: 7-12.
5. Welch GW, Pomare EW. Functional gastrointestinal symptoms in a Wellington community sample. NZ Med J 1990; 103: 418-420.
6. Bi-Zhen W, Qi-Ying P. Functional bowel disorders in apparently healthy Chinese people. Chinese J Epid 1988; 9: 345-349.
7. Drossman DA, Li Z, Andruzzi E, Temple R, Talley NJ, Thompson WG. et al. U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993; 38: 1569-1580.
8. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992; 136: 165-177.
9. Thompson WG, Heaton KW, Smyth T, Smyth C. Irritable bowel syndrome in general practice: prevalence, management and referral. Gut 2000; 46: 78-82.
10. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. C. Functional bowel disorders and D. Functional abdominal pain. In: The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: a Multinational Consensus. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE (editors). Washington: Degnon; 2000. pp. 351-432.
11. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-1741.
12. Thompson WG. The Road to Rome. In: The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: a Multinational Consensus. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE (editors). Washington: Degnon; 2000. pp. 629-635.
13. Patterson WG, Thompson WG, Vanner SJ, Falloon TR, Rosser WW, Birtwhistle RW. et al. Recommendations for the management of irritable bowel syndrome in family practice. Can Med Assoc J 1999; 161: 154-160.
14. Carter Y, Thomas C. Research Methods in Primary Care. Oxford: Radford Press; 1997.
15. Vanner S, Glenn D, Patterson WG, Depew W, Mackenzie T, Djurfeldt M. et al. Diagnosing irritable bowel syndrome: predictive value of the Rome criteria. Gastroenterology 1997; 112: A47.A47.
16. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Comparing Rome I and Rome II criteria for irritable bowel syndrome (IBS) in a prospective survey of the Canadian population. Am J Gastroenterol, in press.
17. Hyams JS. Sorbitol intolerance: an unappreciated cause of functional gastrointestinal complaints. Gastroenterology 1983; 84: 30-33.
18. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333: 1-4.
19. Sullivan MA, Cohen S, Snape WJ. Colonic myoelectrical activity in irritable bowel syndrome. Effect of eating and anticholinergics. N Engl J Med 1978; 298: 878-883.
20. Cowgill GR, Sullivan AJ. Further studies on the use of wheat bran as a laxative. JAMA 1933; 100: 795-802.
21. Jones VA, McLaughlan P, Shorthouse M, Workman E, Hunter JO. Food intolerance: a major factor in the pathogenesis of the irritable bowel syndrome. Lancet 1982; ii: 1115-1117.
22. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232-241.
23. Snook J, Shepherd AH. Bran supplementation in the treatment of the irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 511-514.
24. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499-510.
25. Camilleri M, Choi M-G. Irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 3-15.
26. Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, Naccaratto R. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo controlled, 15-week study. Aliment Pharmacol Ther 1998; 12: 1003-1010.
27. Aziz Q, Thompson DG. Brain-gut axis in health and disease. Gastroenterology 1998; 114: 559-578.
28. Collins SM. The immunoregulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996; 111: 1683-1699.
29. Gwee KA, Graham JC, McKendrick NW, Collins SM, Marshall JS, Walters SJ. et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-153.
30. Chaudhary NA, Truelove SC. The irritable colon syndrome. QJ Med 1962; 31: 307-322.
31. Heaton KW, Thompson WG. The Irritable Bowel Syndrome. Oxford: Fast Facts; 1999.
32. Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC. et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988; 95: 701-708.
33. Whitehead WE, Bosmajian L, Zonderman AB, Costa Jr PT, Schuster MM. Symptoms of psychological distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988; 95: 709-714.
34. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable bowel syndrome. Lancet 1984; ii: 1232-1234.
35. Whorwell PJ. Use of hypnotherapy in gastrointestinal disease. Br J Hosp Med 1991; 45: 27-29.
36. Guthrie E, Creed F, Dawson D, Tomenson B. A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatry 1993; 163: 315-321.
37. Drossman DA, Creed FH, Fava GA, Olden KW, Patrick DL, Toner BB. et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterol Int 1995; 8: 47-90.
38. Nobaek S, Johanssen M-L, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction of abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238.
39. 3 antagonist, in the treatment of non-constipated female IBS patients. Am J Gastroenterol 1999; 94: 2677-2677.
40. Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419-1427.
41. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-1039.
42. 3-receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-1159.
43. 4 agonist tegaserod improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS). Am J Gastroenterol 1999; 94: 2676-2676.
44. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998; 285: 707-715.
45. Baber NS, Dourish CT, Hill DR. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 1989; 39: 307-328.
46. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; ii: 653-654.
47. Thompson WG. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease. Gut 1984; 25: 1089-1092.
48. Bond JH. Screening for colorectal cancer: need for controlled trials. Ann Intern Med 1990; 113: 338-340.